The proteasome inhibitors and anti-CD138/CD38 antibodies are shown to target autoreactive plasma cells in SLE, and we recently found that proteasome inhibitors can target proinflammatory Th17 cells in mice with ESS [110,153,154,155,156]. Here, CD38 is linked to systemic lupus erythematosus.